

Certificate of Analysis for HRP-20266

Lenacapavir

Catalog No. HRP-20266

This reagent is the property of the U.S. Government.

Product Description:

Lenacapavir (Sunlenca; GS-6207) is a first-in-class capsid inhibitor approved by the U.S. FDA as an antiretroviral medication to treat HIV/AIDS patients. Lenacapavir interferes with multiple essential steps of the viral lifecycle dependent on capsids, such as nuclear transport, virus assembly and release, and capsid-core formation. It exhibits antiviral activity at picomolar concentrations against all tested subtypes of human immunodeficiency virus type 1 (HIV-1) and shows high synergy, no cross-resistance, and minimal cytotoxicity with approved antiretroviral drugs.

Lot: 70058726 Manufacturing Date: 08MAR2022

All information below was provided on 30AUG2022 by MedChemExpress, LLC for the bulk material (MedChemExpress lot 66869).

Chemical Name	1H-Cyclopropa[3,4]cyclopenta[1,2]pyrazole-1-acetamide, N-[(1S)-1-[3-[4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-,(3bS,4aR)-
Structure	H F F CI H N O N O O O O O O O O O O O O O O O O
Formula	C ₃₉ H ₃₂ CIF ₁₀ N ₇ O ₅ S ₂
Molecular Weight	968.28
CAS Number	2189684-44-2
Content per Vial	2.0 mg ± 0.3 mg
Appearance	White to light yellow powder
Purity (HPLC)	98.5%

/Ken Crawford/

Ken Crawford 17 MAR 2023

Lead Technical Writer, ATCC Federal Solutions

ATCC®, on behalf of the NIH HIV Reagent Program, hereby represents and warrants that the material provided under this certificate has been subjected by the manufacturer to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.

NIH HIV Reagent Program

www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org
Tel: 888-487-0727 | Fax: 703-365-2898